Abstract
Ovarian ablation has a long-standing history in the treatment of metastatic breast cancer. At the end of the past century, several reports appeared on the beneficial effect of surgical removal of the ovaries in premenopausal women with advanced breast cancer. Subsequently, this treatment became the standard systemic hormone therapy for such patients. However, the disadvantage is that only a minority of patients respond, and the remainder suffer unnecessary treatment morbidity. In a random premenopausal patient population, oophorectomy produced an average 33% objective response rate. In the search for alternatives, analogues of luteinizing hormone-releasing hormone (LH-RH) have been thoroughly investigated in pre- and postmenopausal women. The results obtained have established a place for LH-RH agonists in the treatment of premenopausal women with metastatic breast cancer. In addition, these substances have replaced oophorectomy where indicated in the adjuvant hormonal treatment of premenopausal breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107, 162–165
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Pacini P, Gallo L, Sismondi P, Giai M, Genta F, Mustacchi G, Agostara B, Bolognesi A, Villa E, Schieppati G, Ausili-Cefaro G, Bellantone R, Farris A, Sassi M, Patrone F (1998) Italian breast cancer adjuvant chemo-hormone therapy cooperative trials. Recent Results Cancer Res 152: 453–470
Boccardo F, Blarney R, Klijn J, Tominaga T, Duchatean L, Sylvester R (1999) LH-RH agonist (LH-RH) + tamoxifen (TAM) versus LH-RH-A alone in premenopausal women with advanced breast cancer (ABC): results of a meta-analysis of four trials. Proc Am Soc Clin Oncol 18: 110a (abstract 416)
DeSombre E, Johnson E, White W (1996) Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res 36:3830–3833
Eidne K, Flanagan C, Millar R (1985) Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229: 989
Eidne K, Flanagan C, Harris N, Millar R (1987) Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425–432
Foekens JA, Henkeiman M, Fukkink J, Blankenstein M, Klijn J (1986) Direct effects of LHRH analogs on tumor cells. Eur J Cancer 22: 725 (Abstr. III-s)
Gazet J-C, Coombes R, Ford H, Griffin M, Corbishley C, Markinde V, Lowndes S, Quilliam J, Sutcliffe R (1996) Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer 73: 758–762
Harvey HA, Lip ton A, Santen R, Escher G, Hardy M, Glode L, Segatoff A, Landau R, Schneir H, Max D (1981) Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients. Proc Am Assoc Cancer Res Am Soc Clin Oncol 22: 444 (Abstr. C-436)
Harvey HA, Lipton A, Max D, Pearlman H, Diaz-Porches R, de la Garza J (1984) Effective medical castration produced by the GnRH analog leuprolide in metastatic breast cancer. Proc Am Soc Clin Oncol 3: 111 (Abstr. C-435)
Henderson IC, Canellos G (1980) Cancer of the breast, the pasf decade. Part 1. N Engl J Med 302: 17–30
Hollingsworth A, Lerner M, Lightfoot S, Wilkerson K, Hanas J, McCay P, Brackett D (1998) Prevention of DMBA-inducted rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen. Breast Cancer Res Treat 47: 63–70
Hoogstraten B, Gad-ei-Mawla N, Maloney T, Fletcher W, Vaughn C, Tranum B, Athens J, Costanzi J, Foulkes M (1984) Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study. Cancer 54: 2248–2256
Ingle JN, Krook J, Green S, Kubista T, Everson L, Ahmann D, Chang M, Bisel H, Windschitl H, Twito D, Pfeifle D (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185
Jonat W, Kaufmann M, Blarney R, Sheldon T (1998) The “ZEBRA” study: “Zoladex” (goserelin) vs CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/perimenopausal women aged 50 years or less. International Congress on Breast Cancer, San Antonio, February 27 (abstract p 107), p 41
Klijn JGM, de Jong F (1982) Treatment with a luteinising hormone-releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1: 1213–1216
Klijn JGM, de Jong F, Lamberts S, Blankenstein M (1985) LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873
Miller W, Scott W, Morris R, Fraser H, Sharpe R (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231–233
Nicholson RI, Maynard P (1979) Anti-tumour activity of ICI 11863 0, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer 39: 268–273
Plowman P, Nicholson R, Walker K (1986) Remissions of metastatic breast cancer in postmenopausal women with luteinising hormone-releasing hormone (ICI 11863 0) therapy. Eur J Cancer 22: 746 (Abstr. 111–18)
Pritchard KI, Thomson D, Myers R, Sutherland D, Mobbs B, Meakin L (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787–796
Savino L, Baldini B, Susini T, Pulli F, Antignani L, Massi G (1992) GnRH analogs in gynecological oncology: a review. J Chemother 4: 312–320
Scambia G, Benedetti Panici P, Baiocchi G, Gaggini C, Iacobelli S, Manciso S (1988) Growth inhibitory effect of LH-RH analogs on human breast cancer cells. Anticancer Res 8: 187–190
Schally AV, Redding T, Comaru-Schally A (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68: 281–289
Schinzinger AS (1889) Über Carcinoma mammae. Zbl Chir (Beil) 16: 55–56
Sharoni Y, Bosin E, Minister A, Levy J, Schally A (1989) Inhibition of growth of human mammary tumors cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86: 1648–1651
Taylor C, Green S, Dalton W, Martino S, Rector D, Ingle J, Robert N, Budd G, Paradelo J, Natale R, Bearden J, Mailliard J, Osborne C (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oecol 16: 994–999
Untch M (1998) Endokrine Primärtherapie des präbzw. perimenopausalen Mammakarzinoms mit Leuprorelinacetat-Depot. Deutsche Leuprorelin-Studiengruppe. Zbl Gynakol 120: 286–292
Waxman JH, Harland S, Coombes R, Wrigley P, Malpas J, Powles T, Lister T (1985) The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15: 171–173
Williams MR, Walker K, Turkes A, Blarney R, Nicholson R (1986) The use of an LH-RH agonist (ICI 11863 0, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 629–636
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Höffken, K., Kath, R. (2000). The Role of LH-RH Analogues in the Adjuvant and Palliative Treatment of Breast Cancer. In: Höffken, K., Kath, R. (eds) Peptides in Oncology III. Recent Results in Cancer Research, vol 153. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59587-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-59587-5_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64038-4
Online ISBN: 978-3-642-59587-5
eBook Packages: Springer Book Archive